Biotechnology company running clinical operations, developing and delivering psychedelics to treat addictions and mental conditions Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) has submitted a patent application for a new chemical series of entactogen like molecules.
Entactogen-like molecules are classes of psychoactive substances which produce distinctive emotional and social effects which the company believes have great potential in treating both substance and behavioural addictions.
This patent application covers the new chemical series and signifies a significant step towards the development of next generation entactogens further providing a key milestone in the company’s drug discovery platform.
“The novel entactogen-like molecules being developed at Awakn and protected in this patent, build on our recent filings to establish a strong pipeline of Novel Chemical Entities. These molecules have the potential to revolutionize the treatment of addiction by delivering improved efficacy in a shorter treatment time. Our aim is to treat addiction patients, more rapidly, effectively, and safely than has been possible to date,”said the company’s chief research officer, professor David Nutt.
